Activation function 2 (AF2) of estrogen receptor-α is required for the atheroprotective action of estradiol but not to accelerate endothelial healing

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 32, 2011, Pages 13311-13316

  Billon Galés, Audrey ^a   Krust, Andrée ^b   Fontaine, Coralie ^a   Abot, Anne ^a   Flouriot, Gilles ^c   Toutain, Céline ^a   Berges, Hortense ^a   Gadeau, Alain Pierre ^d   Lenfant, Françoise ^a   Gourdy, Pierre ^a   Chambon, Pierre ^b   Arnal, Jean François ^a  

^a Departments of Clinical Biochemistry and Sports Medicine   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d INSERM   (France)

Author keywords

Atherosclerosis; Nuclear receptor; Transactivating function

Indexed keywords

COMPLEMENT COMPONENT C3; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; THYMIDINE KINASE;

ACTIVATION FUNCTION 2; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ESTROGEN RESPONSIVE ELEMENT; FEMALE; HORMONE ACTION; HORMONE STRUCTURE; IMMUNOSTIMULATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; WILD TYPE;

ANIMALS; AORTA; ATHEROSCLEROSIS; BODY WEIGHT; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION; HELA CELLS; HEP G2 CELLS; HUMANS; MICE; MICE, KNOCKOUT; ORGAN SIZE; PROTECTIVE AGENTS; REPRODUCIBILITY OF RESULTS; TRANSCRIPTIONAL ACTIVATION; UTERUS; WOUND HEALING;

MUS;

EID: 80051954941     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1105632108     Document Type: Article

References (48)

1. Kalin M.F., Zumoff B. (1990) Sex hormones and coronary disease: A review of the clinical studies. Steroids 55:330-352. (Pubitemid 20309765)
2. Dubey R.K., Imthurn B., Barton M., Jackson E.K. (2005) Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen. Cardiovasc Res 66:295-306. (Pubitemid 40471044)
3. Grodstein F., et al. (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335:453-461. (Pubitemid 26269944)
4. Mikkola T.S., Clarkson T.B. (2002) Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 53:605-619. (Pubitemid 34175253)
5. Arnal J.F., et al. (2010) Estrogen receptors and endothelium. Arterioscler Thromb Vasc Biol 30:1506-1512.
6. Rossouw J.E., et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333. (Pubitemid 34761611)
7. Anderson G.L., et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712. (Pubitemid 38489892)
8. Rossouw J.E., et al. (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297:1465-1477. (Pubitemid 46556472)
9. Krasinski K., et al. (1997) Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 95:1768-1772. (Pubitemid 27164391)
10. Elhage R., et al. (1997) 17 beta-estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 17:2679-2684. (Pubitemid 28016008)
11. Rosenfeld M.E., et al. (2002) Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice. Atherosclerosis 164:251-259. (Pubitemid 35223074)
12. Stevenson J.C. (2009) Type and route of estrogen administration. Climacteric 12(Suppl 1):86-90.
13. Ascenzi P., Bocedi A., Marino M. (2006) Structure-function relationship of estrogen receptor alpha and beta: Impact on human health. Mol Aspects Med 27:299-402. (Pubitemid 44255847)
14. Tora L., et al. (1989) The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59:477-487. (Pubitemid 19284461)
15. Métivier R., Penot G., Flouriot G., Pakdel F. (2001) Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: Requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains. Mol Endocrinol 15:1953-1970. (Pubitemid 33026110)
16. Levin E.R. (2005) Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 19:1951-1959.
17. Kim K.H., Bender J.R. (2009) Membrane-initiated actions of estrogen on the endothelium. Mol Cell Endocrinol 308:3-8.
18. Brouchet L., et al. (2001) Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation 103:423-428. (Pubitemid 32105983)
19. Pare G., et al. (2002) Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90:1087-1092. (Pubitemid 34627907)
20. Hodgin J.B., et al. (2001) Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J Clin Invest 107:333-340. (Pubitemid 32157965)
21. Billon-Galés A., et al. (2009) Endothelial estrogen receptor-alpha plays a crucial role in the atheroprotective action of 17beta-estradiol in low-density lipoprotein receptor-deficient mice. Circulation 120:2567-2576.
22. Dupont S., et al. (2000) Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 127:4277-4291.
23. Pendaries C., et al. (2002) The AF-1 activation-function of ERalpha may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc Natl Acad Sci USA 99:2205-2210.
24. Billon-Galés A., et al. (2009) The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta-estradiol. Proc Natl Acad Sci USA 106:2053-2058.
25. Danielian P.S., White R., Lees J.A., Parker M.G. (1992) Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 11:1025-1033.
26. Mérot Y., et al. (2004) The relative contribution exerted by AF-1 and AF-2 transactivation functions in estrogen receptor alpha transcriptional activity depends upon the differentiation stage of the cell. J Biol Chem 279:26184-26191.
27. Berry M., Metzger D., Chambon P. (1990) Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811-2818.
28. Gourdy P., et al. (2003) The atheroprotective effect of 17 beta-estradiol is not altered in P-selectin- or ICAM-1-deficient hypercholesterolemic mice. Atherosclerosis 166:41-48. (Pubitemid 35449599)
29. Nathan L., Pervin S., Singh R., Rosenfeld M., Chaudhuri G. (1999) Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbits in vivo : Possible mechanisms for gender differences in atherosclerosis. Circ Res 85:377-385. (Pubitemid 29398870)
30. O'Lone R., et al. (2007) Estrogen receptors alpha and beta mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. Mol Endocrinol 21:1281-1296. (Pubitemid 46991958)
31. Green S., et al. (1986) Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A. Nature 320:134-139. (Pubitemid 16105150)
32. Tzukerman M.T., et al. (1994) Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21-30. (Pubitemid 24034253)
33. Metzger D., Ali S., Bornert J.M., Chambon P. (1995) Characterization of the aminoterminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. J Biol Chem 270:9535-9542.
34. McKenna N.J., O'Malley B.W. (2002) Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465-474. (Pubitemid 34260872)
35. Webb P., et al. (1998) Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol 12:1605-1618. (Pubitemid 30665208)
36. Onate S.A., et al. (1998) The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem 273:12101-12108. (Pubitemid 28240570)
37. Benecke A., Chambon P., Gronemeyer H. (2000) Synergy between estrogen receptor alpha activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2. EMBO Rep 1:151-157.
38. Kobayashi Y., et al. (2000) p300 mediates functional synergism between AF-1 and AF-2 of estrogen receptor alpha and beta by interacting directly with the N-terminal A/B domains. J Biol Chem 275:15645-15651. (Pubitemid 30366859)
39. Borjesson A.E., et al. (2011) Roles of transactivating functions 1 and 2 of estrogen receptor-alpha in bone. Proc Natl Acad Sci U S A 108:6288-6293.
40. Chambliss K.L., et al. (2010) Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest 120:2319-2330.
41. Toutain C.E., et al. (2009) Estrogen receptor alpha expression in both endothelium and hematopoietic cells is required for the accelerative effect of estradiol on reendothelialization. Arterioscler Thromb Vasc Biol 29:1543-1550.
42. Fontaine V., et al. (2006) Essential role of bone marrow fibroblast growth factor-2 in the effect of estradiol on reendothelialization and endothelial progenitor cell mobilization. Am J Pathol 169:1855-1862. (Pubitemid 351182014)
43. Leen L.L., et al. (2008) Estrogen-stimulated endothelial repair requires osteopontin. Arterioscler Thromb Vasc Biol 28:2131-2136.
44. Billon A., et al. (2008) The estrogen effects on endothelial repair and mitogen-activated protein kinase activation are abolished in endothelial nitric-oxide (NO) synthase knockout mice, but not by NO synthase inhibition by N-nitro-L-arginine methyl ester. Am J Pathol 172:830-838. (Pubitemid 351354554)
45. Hodgin J.B., Knowles J.W., Kim H.S., Smithies O., Maeda N. (2002) Interactions between endothelial nitric oxide synthase and sex hormones in vascular protection in mice. J Clin Invest 109:541-548. (Pubitemid 34171786)
46. Lenfant F., Trémollières F., Gourdy P., Arnal J.F. (2011) Timing of the vascular actions of estrogens in experimental and human studies: Why protective early, and not when delayed? Maturitas 68:165-173.
47. Penot G., et al. (2005) The human estrogen receptor-alpha isoform hERalpha46 antagonizes the proliferative influence of hERalpha66 in MCF7 breast cancer cells. Endocrinology 146:5474-5484. (Pubitemid 41653062)
48. Filipe C., et al. (2008) Estradiol accelerates endothelial healing through the retrograde commitment of uninjured endothelium.AmJ PhysiolHeart Circ Physiol 294:H2822-H2830.